PPCB Propanc Biopharma Inc. Forward P/S Multiple

Propanc Biopharma Inc. (PPCB) - corporate logo

Cost optimization through outsourcing drug synthesis to CDMO centers supports the projected market cap-to-revenue dynamics, where the current metric is . Propanc Biopharma Inc (PPCB) is creating long-term growth potential through the development of unique proenzymes targeting cancer stem cells. Steady confidence from the medical community regarding metastasis therapy minimizes operational risks, as this chart clearly illustrates.

PPCB (Propanc Biopharma) Price to Expected Revenue Ratio history from 07/04/2022 to 11/13/2026

propanc.com - analytical breakdowns and key metrics (PPCB)

- current price and projected stock value:
Stock Price Propanc Biopharma|PPCB - Analyst Target Range
- market capitalization data:
Market Capitalization Propanc Biopharma|PPCB - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Propanc Biopharma|PPCB - Total Net Assets|Market Capitalization to Book Value Ratio propanc.com|PPCB - Company Assets
- debt and liquidity data:
Total Debt to Capital Propanc Biopharma Inc|PPCB - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Propanc Biopharma|PPCB - Aggregate Debt Obligations|Debt to Book Value Propanc Biopharma|PPCB - Amount of Long-Term Liabilities|Company Short-Term Debts Propanc Biopharma|Quick Ratio propanc.com
- net income and valuation multiples indicators:
PPCB - Company Net Income|Expected Profit Propanc Biopharma Inc|PPCB - Company Value to Net Income|Forward P/E Multiple Propanc Biopharma|PPCB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Propanc Biopharma|PPCB - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Propanc Biopharma|PPCB - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months propanc.com|PPCB - Earnings per share trend in current year|Net earnings per share growth forecast for next year Propanc Biopharma Inc
- issuer revenue and sales details:
PPCB - Company Sales Revenue|Company Projected Revenue Propanc Biopharma|PPCB - Price to Sales|Price-to-Projected Revenue Ratio Propanc Biopharma
Summary company analysis:Propanc Biopharma, Inc. (PPCB)
Product sample of Propanc Biopharma Inc.

The forward P/S is calculated as the ratio of current market capitalization to expected revenue for the following year, measuring the market valuation of each unit of projected sales. The forward P/S trend for Propanc Biopharma Inc (PPCB) reflects market confidence in the commercialization of Propanc Biopharma Inc (PPCB) enzyme preparations, where the stability of the line confirms a resilient consensus regarding revenues from joint developments in pancreatic cancer therapy.

Competing companies

Forward P/S Multiple GMAB (Genmab)|Projected Price to Revenue Exelixis Inc|Nuvalent Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kymera Corp|IDYA (IDEAYA Biosciences) - Forward Price-to-Revenue Multiple|ELVN: Price to Expected Revenue Ratio|ORIC (ORIC Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Relay Therapeutics Inc RLAY|Forward P/S Multiple NRIX|Tyra Corp - Market Cap to Projected Revenue|Verastem, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales GLUE|CGEM: Forward Price-to-Revenue Multiple|Immuneering Corp - Price to Expected Revenue Ratio|CCCC: Forward P/S Multiple|Black Diamond Therapeutics, Inc - Forward Price to Sales|RPTX (Repare Therapeutics) - Forward P/S Multiple|Market Cap to Future Revenue Ratio pmvpharma.com PMVP|Price-to-Projected Revenue Ratio Karyopharm Therapeutics (KPTI)|BGMS (Bio Green Med Solution Inc.) - Forward Price to Sales|Forward P/S Multiple AADI (Aadi Bioscience, Inc.)|Forward P/S Multiple Aileron Therapeutics Inc ALRN|BPMC - Price-to-Projected Revenue Ratio|Future Price to Revenue GLYC|SWTX (SpringWorks Therapeutics, Inc.) - Forward Price-to-Revenue Multiple